BeOne Medicines

Update in progress

ONC (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

BeOne Medicines AG is a Basel-based oncology company focused on discovering and developing cancer therapies for patients in the US, China, Europe and worldwide. Its commercial products include BRUKINSA (BTK inhibitor), TEVIMBRA (anti‑PD‑1), SYLVANT (multicentric Castleman disease), BAITUOWEI (pre/perimenopausal breast cancer) and PARTRUVIX for solid tumors. It has extensive clinical programs and collaborations (Amgen, BMS, Bio-Thera, EUSA, Luye, Novartis). Formerly BeiGene, renamed May 2025. Founded 2010.

Company score

Sentiment: 0.43; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.27; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive